Lifevantage Corp. | Income Statement

Fiscal year is July-June. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
213,968.00
190,336.00
206,540.00
199,489.00
203,204.00
Cost of Goods Sold (COGS) incl. D&A
33,194.00
28,010.00
33,932.00
33,456.00
34,848.00
Gross Income
180,774.00
162,326.00
172,608.00
166,033.00
168,356.00
SG&A Expense
161,326.00
148,427.00
159,194.00
161,584.00
158,033.00
EBIT
19,448.00
13,899.00
-
4,449.00
10,323.00
Unusual Expense
-
-
-
350.00
-
Non Operating Income/Expense
384.00
159.00
1,409.00
619.00
319.00
Interest Expense
3,177.00
3,087.00
3,321.00
570.00
456.00
Pretax Income
16,655.00
10,653.00
8,684.00
2,910.00
9,548.00
Income Tax
5,272.00
3,666.00
2,578.00
1,302.00
3,787.00
Consolidated Net Income
11,383.00
6,987.00
6,106.00
1,608.00
5,761.00
Net Income
11,383.00
6,987.00
6,106.00
1,608.00
5,761.00
Net Income After Extraordinaries
11,383.00
6,987.00
6,106.00
1,608.00
5,761.00
Net Income Available to Common
11,383.00
6,987.00
6,106.00
1,608.00
5,761.00
EPS (Basic)
0.70
0.49
0.42
0.11
0.41
Basic Shares Outstanding
15,113.00
13,899.00
13,730.00
13,881.00
13,992.00
EPS (Diluted)
0.71
0.49
0.42
0.11
0.41
Diluted Shares Outstanding
15,942.70
14,150.30
14,531.00
14,118.00
14,136.00
EBITDA
21,566.00
16,184.00
15,309.00
6,092.00
11,648.00

About Lifevantage

View Profile
Address
9785 South Monroe Street
Sandy Utah 84070
United States
Employees -
Website http://www.lifevantage.com
Updated 07/08/2019
LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and skin care products. The firm operates through the Americas; and Asia or Pacific and Europe geographical segments. It currently focuses on oxidative stress solutions, particularly the activation of nuclear factor which relates to cardiovascular, central nervous system, inflammatory and metabolic diseases as well as other health related disorders.